Evidence map›Paper›PMID 36124341›Full record

Observational studyClinical cardiology2022

Use of lipid-lowering therapies in patients with chronic kidney disease and atherosclerotic cardiovascular disease: 2-year results from Getting to an imprOved Understanding of Low-Density lipoprotein cholesterol and dyslipidemia management (GOULD).

Aleesha Shaik, Mikhail Kosiborod, James A de Lemos, Qi Gao, Katherine E Mues, Shushama Alam, Deepak L Bhatt, Christopher P Cannon, Christie M Ballantyne, Robert S Rosenson and 1 more

Registry-linked trialOpen access · goldFull text readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Clinical cardiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02993120 (Getting to an Improved Understanding of Low-Density Lipoprotein Cholesterol and Dyslipidemia Management), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02993120 completednot on this map

Getting to an Improved Understanding of Low-Density Lipoprotein Cholesterol and Dyslipidemia Management (GOULD) a Registry of High Cardiovascular Risk Subjects in the United States

TypeobservationalSponsorAmgenRan2016 to 2021Enrolled5,006ConditionsMedical Conditions to be Studied, Dyslipidemia, ASCVD Management
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Observational
  4. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 2 countries.

Aleesha ShaikThe Cardiometabolic Disorders Unit, Icahn School of Medicine at Mount Sinai, New York, New York, USA.ORCID http://orcid.org/0000-0003-0850-9285
Mikhail KosiborodSaint Luke's Mid America Heart Institute, University of Missouri-Kansas City, Kansas City, Missouri, USA.
James A de LemosDivision of Cardiology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Qi GaoBaim Institute for Clinical Research, Boston, Massachusetts, USA.
Katherine E MuesAmgen Inc., Thousand Oaks, USA.
Shushama AlamAmgen Inc., Thousand Oaks, USA.
Deepak L BhattBrigham and Women's Hospital Heart and Vascular Center and Harvard Medical School, Boston, Massachusetts, USA.
Christopher P CannonBrigham and Women's Hospital Heart and Vascular Center and Harvard Medical School, Boston, Massachusetts, USA.ORCID http://orcid.org/0000-0003-4596-2791
Christie M BallantyneDepartment of Medicine, Baylor College of Medicine, Houston, Texas, USA.
Robert S RosensonThe Cardiometabolic Disorders Unit, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
GOULD Investigators
Amgen (United States) · USBrigham and Women's Hospital · USIcahn School of Medicine at Mount Sinai · USBaim Institute for Clinical Research · USBaylor College of Medicine · USThe University of Texas Southwestern Medical Center · USUNSW Sydney · AU

Funding

Amgen
6 · The paper itself

Abstract

backgroundChronic kidney disease (CKD) is a known risk factor of atherosclerotic cardiovascular disease (ASCVD). Per the 2018 American Heart Association/American College of Cardiology cholesterol guidelines, high-risk ASCVD patients with CKD and low-density lipoprotein cholesterol (LDL-C) levels OBJECTIVE/

methodsWe examined the changes in use of lipid lowering therapies (LLT) over two years in 3304 patients with ASCVD and CKD in the Getting to an imprOved Understanding of Low-Density Lipoprotein Cholesterol and Dyslipidemia Management (GOULD) observational cohort study.

resultsOf those with eGFR <60 ml/min/1.73 m

conclusionDespite the recommendations of multiscociety guidelines, statin use, while high, is not ubiquitous and rates of high-intensity statin and ezetimibe use remain low in patients with CKD. There remains a significant opportunity to optimize LLT and achieve atheroprotective cholesterol levels in the CKD population.

Indexed as

Anticholesteremic AgentsAtherosclerosisCardiovascular DiseasesDyslipidemiasHydroxymethylglutaryl-CoA Reductase InhibitorsRenal Insufficiency, ChronicCholesterolCholesterol, LDLEzetimibeHumansAnticholesteremic AgentsCholesterolCholesterol, LDLEzetimibeHydroxymethylglutaryl-CoA Reductase Inhibitorsatherosclerosischolesterolchronic kidney diseasecoronary artery diseaseezetimibelipidsstatins

Identifiers

PMID36124341
PMCPMC9748744
OpenAlexW4296389376

What OpenQuestion holds

Textfull text, public
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.